For the first half of this year, I Sec, as ICICI Securities is popularly known, is fourth in Bloomberg's M&A league table, with $4.2 billion worth of deals. This is largely due to its advisory role in Ranbaxy Laboratories' $4-billion merger with Sun Pharmaceuticals. For 2013 and 2012, I Sec was 20th and 27th, respectively, on the list.
"We have prepared well in the last two years, when there was a lull in the market," says Anup Bagchi, managing director and chief executive of I Sec.
In 2013, M&A activity dropped to $62 billion from $165 billion in 2012, as policy paralysis crippled India's economic growth. For the first half of this year, M&A activity rose to $54 billion. And, the momentum is expected to continue, as the new government works on fuelling economic growth.
Until April 2012, I Sec, part of domestic financial behemoth ICICI Group, was largely in the business of capital markets and private equity advisory. Till then, the group's M&A advisory team was under ICICI Bank. As the group decided to keep all its investment banking business under one roof, it shifted its 12-member M&A advisory team to I Sec.
"One big deal can really swing one's position in the league table," says Ajay Saraf, executive director at ICICI Securities. "So, while we do regular bread-and-butter deals, we also keep our eyes on billion-dollar ones," he says.
I Sec's strength is largely in domestic deals. Its capability in high-value cross-border deals is limited. In October 2013, it tied up with Tokyo Stock Exchange-listed GCA Savvian to garner a slice of the growing India-Japan M&A pie.